The need for equivalent results of routine measurement procedures for the alcohol biomarker carbohydrate-deficient transferrin (CDT) has been recognized by the IFCC. This article describes a project to harmonize CDT as conducted by an IFCC working group initiated for this purpose.
cases of a 2-to 3-fold increase of disialotransferrin, asialotransferrin becomes measurable (6 ) . With abstinence or a major reduction of alcohol consumption, disialotransferrin slowly decreases (half-life approximately 10 days), and baseline values are reached after 2-5 weeks (7, 8 ) .
The measurement of CDT is challenging, owing to the variety of transferrin glycoforms. Routine measurement procedures (MPs) differ in their underlying analytical principles and measure either disialotransferrin specifically or a sum of di-, mono-, and asialotransferrin (9 ) . The resulting variation in measurand between routine MPs leads to noncomparability of CDT values and reference intervals/decision limits and, consequently, to difficulty with both result interpretation and understanding of the diagnostic value of CDT. To improve routine clinical use, the IFCC initiated a working group (WG-CDT) to achieve equivalence of results across routine MPs. ISO 17511 defines 5 categories of reference systems for metrological traceability. The aim of the WG-CDT was to develop a reference system with a primary reference measurement procedure and primary calibrators giving metrological traceability to the Système International (SI).
Investigation of disialotransferrin as a primary calibrator revealed complications. There was a suspicion that use of disialotransferrin as a primary calibrator could be problematic because the candidate reference measurement procedure (cRMP) quantifies disialotransferrin in relation to the sum of all transferrin glycoforms, and these glycoforms could have different molar absorptivities. In addition, the availability, definition, and estimation of the purity of disialotransferrin were not satisfactory. Because resolution of these technical issues might take a long time or even prove impossible, the WG-CDT decided to aim for a lower category in the hierarchy of metrological traceability.
HPLC with photometric detection of the irontransferrin complex at 470 nm has been developed as a consensus designated comparison measurement procedure (cRMP) for value assignment (10, 11 ) . The cRMP is implemented in an international network of reference laboratories (12 ) . Results of the cRMP are expressed as a percentage of CDT (disialotransferrin) and in this article denoted as IFCC CDT units. Exploration of candidate reference materials (cRMs) revealed the potential to use native sera and the unsuitability of disialotransferrin-spiked human sera to achieve harmonization of CDT routine MPs (12, 13 ) .
Recently the AACC started an initiative that created the International Consortium for Harmonization of Clinical Laboratory Results (ICHCLR). Within the framework of the ICHCLR, a toolbox of technical procedures to achieve harmonization for a measurand has been developed (14, 15 ) . We used this generic process to facilitate fast and efficient harmonization to design this investigation for harmonization of routine MPs for CDT.
Materials and Methods

DESIGN: TOOLBOX TO HARMONIZATION
The study was designed according to the integrated harmonization protocol using the toolbox of technical procedures of the ICHCLR to achieve harmonization for a measurand. For details of the protocol, see www. harmonization.net. The first part of the protocol is an assessment study to determine if harmonization is technically achievable. We derived relevant data on reproducibility, relationship, and heterogeneity of routine MPs from triplicate assays of 40 patient serum samples, measured with the routine MPs and the cRMP. We evaluated commutability of cRMs from triplicate assays of 40 patient samples and the respective cRMs with routine MPs and the cRMP. cRMs were stored at various temperatures and measured periodically during 3 years to evaluate long-term stability. Repeated value assignment to the same set of cRMs was done to test reproducibility of value assignment with the cRMP.
The second part of the harmonization toolbox requires an effort to achieve harmonization and assess its success. In 2 independent pilot studies, manufacturers were supplied with cRMs and blind (CDT concentration not supplied) individual patient serum samples. We used the intermeasurement CV (inter-MP CV) after calibration with the cRMs, the recovery of the value assigned with the cRMP, and the proportion of results within total allowable error (TEa) as parameters to estimate the success of harmonization. Table 1 shows the samples included in the study. One batch of frozen cRMs (Fro cRM 1) was used for stability testing. One batch of frozen cRMs (Fro cRM 2), 3 batches of lyophilized cRMs (Lyo cRM 2, 3, and 4), and 40 patient serum samples were used to evaluate other aspects. A batch of frozen cRMs (Fro cRM 3) and 27 patient samples were used to evaluate effort and success. All samples were sera from heavy and nonheavy drinkers, and the cRMs consisted of pooled samples. Unless noted otherwise, samples were stored at Ϫ70°C or below.
SAMPLES AND MEASUREMENTS
Samples were tested with the cRMP, frozen at Ϫ70°C, and shipped on dry ice from the central laboratory in the Netherlands to the respective network laboratories and manufacturers. All samples were collected within the European Union according to the procedures approved by the ethics committee at the Queen Beatrix Hospital and in accordance with the Helsinki Declaration.
MEASUREMENT PROCEDURES
We used the following CDT measurement procedures: (a) the cRMP on the basis of HPLC (11 ) (9 ) . In this article, the measurement procedures are referred to as cRMP, Analis, Bio-Rad, Helena, Recipe, Sebia, and Siemens.
STATISTICS
Reproducibility was derived from the CVs of triplicate assays. Linear regression results included the correlation coefficient (r), slope, and intercept calculated with nonparametric regression analysis according to Passing and Bablok (20 ) . We assessed commutability with nonparametric regression analysis according to Passing and Bablok, Bland-Altman plots, and normalized residuals (21 ) . We calculated analytical goals for imprecision with CV A Յ f CV I in which CV A was the analytical goal for imprecision, CV I the intraindividual CV, and f the factor for optimum (0.25), desirable (0.50), and minimum (0.75) CV A (22 ) .
We calculated total allowable error with TEa% ϭ f 1 (0.25 CV I ) ϩ f 2 (CV I 2 ϩ CV G 2 ) 1/2 in which CV G is the interindividual variation and f 1 and f 2 are factors for optimum (0.25 and 0.125), desirable (0.5 and 0.250), and minimum (0.75 and 0.375) TEa (22 ) .
Results and Discussion
Parts of the harmonization process were (a) assessment of the harmonization potential of routine methods, (b) assessment of harmonization tools, and (c) assessment of the success to accomplish harmonization.
ASSESSMENT: HARMONIZATION POTENTIAL
Harmonization potential depends on the analytical characteristics of the routine MPs. Table 2 shows analytical characteristics of the CDT routine MPs. The reproducibility was expressed as the intrameasurement procedure CV (intra-MP CV), derived from triplicate measurements of 40 patient samples, which ranged from 1.1% for Analis to 2.8% for Recipe. On basis of data reported by Ricos (23 ) (intra-individual CV of CDT ϭ 7.1%), the allowable imprecision is 1.8% (optimum), 3.6% (desirable), and 5.3% (minimum). Routine MPs included in this study met the criterion for desirable imprecision. It can be concluded that the reproducibility of these routine MPs allows harmonization of their results, with the limitation that this interpretation is based on within-run CVs and not total CVs.
The third column of Table 2 shows the relationship between the respective routine MPs and the cRMP in terms of the correlation coefficient (r), slope, and intercept. Supplemental Fig. 1 , which accompanies the online version of this article at http://www. clinchem.org/content/vol60/issue7, gives a graphical representation of data. Visual inspection of online Supplemental Fig. 1 and the numerical values of r in Table  2 (criterion Ͼ0.99) suggest a linear relationship, which allows relatively easy harmonization. The 95% CIs of the intercept of all routine MPs except Bio-Rad did not include 0.00. This may have resulted from the manufacturer calibration for the Siemens procedure or some nonspecificity influence for the CE and HPLC procedures, and suggests that a multiple-point calibration is required to achieve harmonization. Table 2 also shows the mean inter-MP CV for 40 samples, measured by the routine MPs and after mathematically simulated harmonization (on the basis of value reassignment derived from the regression of results) vs the c-RMP. From these simulated-calibrated results, the inter-MP CV was calculated. The inter-MP CV after simulation calibration was only the contribution of the heterogeneity of the routine MPs (with a small component for imprecision, which is limited as samples are assayed in triplicate). The inter-MP CV of 4.7% was within the bias criterion of 5% and reflected a substantial but just acceptable degree of heterogeneity of the routine MPs. The WG-CDT thus concluded that the harmonization potential of the routine MPs, expressed in terms of reproducibility, relationship, and heterogeneity, was sufficient to allow harmonization.
ASSESSMENT: TOOLS
After reaching the conclusion that the CDT routine MPs have characteristics that allow harmonization, we pursued the next step in the toolbox, assessment of harmonization tools. Requirements to do this include commutable and stable reference materials with reliably assigned values. Pilot studies demonstrated that cRMs with spiked disialotransferrin, as well as several types of lyophilized cRMs, were not suitable (12, 13 ) . Several batches of the most promising lyophilized cRMs (native human serum stabilized with a cryolyoprotectant) and a batch of frozen cRMs (native human sera) were investigated.
Online Supplemental Fig. 1 provides information about potential commutability. Results of both patient samples and cRMs from the routine MPs were plotted against the cRMP. cRMs were commutable when their results indicated the same relationship between MPs, as observed for patient samples within statistically meaningful limits, or they visually coincided with results for the patients. Visual inspection of online Supplemental Commutability can be defined more precisely with normalized residuals. This is shown in online Supplemental Table 1 . Residuals exceeding 2 (or Ϫ2) indicate noncommutability. For Sebia, the residuals for lyophilized cRMs of batches 2 and 3 range from Ϫ2.0 to Ϫ4.1 and confirm the noncommutability suggested by the visual inspection of Fig. 1 . Residuals for Sebia with lyophilized cRMs batch 4 and for Analis with lyophilized cRMs batches 3 and 4 lie within the criterion range for commutability, but they trend in the same direction (all negative for Sebia, all positive for Analis), raising a suspicion of lesser, although acceptable, commutability. In general, residuals for the 5 levels of frozen cRMs (Fro cRM 2) are lower than for the lyophilized cRMs, suggesting these materials have the best commutability. Stability of the frozen cRMs was investigated by storing material at Ϫ20°C and Ͻ Ϫ70°C. CDT was measured with 3 methods (HPLC, CE, and immunoassay) after 3, 6, 15, 24, and 36 months. A significant change in measured CDT was observed in cRMs stored at Ϫ20°C as measured with HPLC and CE. Detailed results are given in online Supplemental Table 2 . It can be concluded that frozen cRMs are stable for at least 3 years when stored below Ϫ70°C. Table 3 shows the reliability of value assignment with the cRMP. The same batch of frozen cRMs was targeted twice by the network of 6 reference laboratories, the first time in April 2013 and the second time in October 2013. Originally, a 4-level set of cRMs was foreseen, but following the request of manufacturers, a fifth level was included later. Therefore, results of this additional level are missing in the April 2013 analysis. It can be seen that the April and October replications are very close and not statistically different (t-test; P Ͻ 0.05). The rightmost column shows the assigned values with the expanded uncertainty at k ϭ 2. The uncertainty is low because values are assigned on 2 occasions in triplicate by 6 reference laboratories.
The toolbox of the ICHCLR also considers sustainability, availability, and costs of the cRMs. Only native human sera are suitable as calibrators, and the availability of sufficient sera with high CDT (of persons with chronic alcohol overconsumption) was a point of concern. However, a public campaign to get donors had a good response, so sustainable availability of cRMs can be achieved with an acceptable cost (Ͻ€300 per set of 5 levels). A final point addressed by the toolbox is the intention of manufacturers to implement harmonization, when the assessment has shown that harmonization is technically achievable and suitable materials can be made available. From the beginning, the CDT-WG collaborated with the manufacturers and they had expressed the clear intention to adopt harmonization.
SUCCESS OF HARMONIZATION
Two pilot efforts were organized to test that harmonization of CDT could be achieved. Six manufacturers were supplied with the frozen cRMs and blind individual patient serum samples and asked to submit CDT results both before and after calibration with the frozen cRMs. Blind sample values were assigned by the IFCC network. Reduction of inter-MP CV and recovery of the assigned values by the manufacturers were used as parameters to define the degree of harmonization success. The combined results of the 2 pilot efforts can be seen in Table 4 . The left part shows the results of routine MPs. It can be seen that for the 20 common individual patient samples (CDT levels from high normal 1.5% to increased 6.0%), the mean inter-MP CV decreased from 8.8% (manufacturer calibrated) to 3.4% (cRM calibrated). The right part of Table 4 shows the recovery of the targets in IFCC CDT units (% disialotransferrin). The mean target value in 20 common patients was 3.09% (Table 4 ). The mean of routine MPs after calibration with the frozen cRMs was 3.07% (recovery of 99%), ranging from 2.97% (recovery 96%) for Helena to 3.13% (recovery 101%) for Sebia.
Previous studies (12, 14 ) indicated that the success of harmonization might be limited in samples with either a low (Ͻ1.3%) CDT concentration or in samples with a high (Ͼ10%) trisialotransferrin concentration. To address these potential limitations, 3 samples with a low CDT and 4 samples with a high native trisialotransferrin concentration were included. Results are shown in Table 4 . For the samples with a low CDT, the inter-MP CV before calibration was much higher than in common patient samples (21.1% vs 8.8%). Calibration with the cRMs reduced the inter-MP CV to 9.6%, but this is still much higher than in common patient samples (3.4%). The mean measured CDT after calibration was 1.28% vs 1.30% (target cRMP), which implies a recovery of 98%, being very close to the recovery of 99% in common patient samples. Trisialotransferrin usually occurs in concentrations around 5%, but in about 1% of the population a high percentage is found (5, 6 ) . Increased trisialotransferrin concentrations are not related to alcohol consumption (5 ). The inter-MP CV before calibration was higher than in common patient samples (13.9% vs 8.8%) and remained higher after calibration (9.3% vs 3.4%) ( Table 4 ). The mean measured CDT after calibration was 4.05% (mean recovery 94%; range 82% for Analis to 108% for BioRad) vs 4.30% (target cRMP). The success of harmonization in terms of reduction of inter-MP CVs and recovery of the mean CDT concentration in blind samples is shown in Table 4 . Another approach is to judge the achieved degree of harmonization in individual patient samples with the total allowable error as criterion (combines bias and imprecision into 1 number). By use of the CV I of 7.1% and CV G of 38.7% of the Ricos lists (23 ), total allowable errors of 7.8% (optimum), 15.6% (desirable), and 23.6% (minimum) can be calculated. In Fig. 2 , the remaining bias after calibration with the cRMs is plotted against the CDT concentration with the limits shown for the optimum, desirable, and minimum total allowable error. Visual inspection shows that most results were within the optimum allowable total error window. Two results in samples with a low CDT were outside the minimum total allowable error. Additionally, Analis results in samples with a high trisialotransferrin were just within the minimum total allowable error window.
Online Supplemental Table 3 displays the percentages of results that met the respective criteria, with differentiation by the respective groups (common patient samples, low CDT, high trisialotransferrin, overall) and routine MPs (6 manufacturers and overall). In the common patient group, 100% of the overall harmonized results met the minimum criterion, 99% were within the desirable limits, and 88% were within the optimum limits. In the high trisialotransferrin group, these percentages were 100%, 94%, and 67%. In the low CDT group, they were 88%, 75%, and 25%. Routine MP specific results are shown in Table 4 .
STATUS OF THE HARMONIZATION PROCESS OF CDT
The CDT-WG addressed all topics of the integrated harmonization protocol of the ICHCLR. In the first assessment step, it was established that harmonization of the routine MPs was feasible. The reproducibility of the routine MPs was good and routine MPs showed a linear relationship with the cRMP, which allowed for a proportional correction to calibration to be implemented. Significant intercepts revealed that multilevel calibration was required. The routine MPs demonstrated some degree of heterogeneity among different individual patient samples but within acceptable limits. Consequently, the CDT-WG concluded that the harmonization potential of the CDT routine MPs was good enough to warrant a harmonization effort.
In the second assessment step, the tools for harmonization were investigated. On the basis of the data, the CDT-WG concluded that frozen native human sera, targeted with the cRMP, were a suitable tool for harmonization. The CDT-WG also concluded that, given the assessment of harmonization potential of the routine MPs and the suitability of harmonization tools, harmonization of CDT was technically achievable.
On the basis of this conclusion, the harmonization process was piloted and its success was evaluated. Harmonization was successful on the basis of results for 20 individual patient samples having a reduction of the inter-MP CV from 8.8% to 3.4% and a 99% recovery of the cRMP assigned values. Samples with a low CDT concentration demonstrated a good recovery with a less satisfying but clinically acceptable inter-MP CV. Some methods demonstrated interference by increased concentrations of trisialotransferrin. A possible explanation could be the method used for integration of peaks in these samples, and this should be addressed by the manufacturers.
In a recent meeting of the CDT-WG and the manufacturers, it was concluded that all prerequisites for harmonization of CDT were fulfilled and it was decided to implement harmonization. According to ISO 17511, the WG-CDT proposes the finally selected cRM as a candidate international conventional calibrator and the cRMP as a candidate international conventional reference measurement procedure.
From the experiences of the WG-CDT, some general conclusions can be made. First, the harmonization process takes a long time (the working group has existed for 9 years) but the ICHCLR toolbox is an efficient design to shorten the process. Second, in working toward the achievement of equivalent results, there may be reasons to change the approach when standardization is not possible or takes too long; harmonization provides a good alternative. However, it is preferable to establish provisions for long-term stability of a reference system (i.e., standardization) whenever that is possible. Third, criteria should be developed for the required degree of equivalence to warrant a harmonization effort. In this article, reduction of the interprocedure CV, recovery of the value assigned with the cRMP, and the proportion of results within the limits of total allowable error were explored but no conclusive general criteria were given. However, any criterion is arbitrary and criteria for each measurand may be different and should be considered in relation to clinical use.
